A year ago, the financial regulatory authority issued guidance on driving high-quality development in health insurance, laying out a transformation roadmap for the industry. Reviewing the past twelve months, the sector has moved forward on two parallel fronts: product and service innovation, alongside regulatory correction. Beyond product changes and tighter oversight, policy support has also been intensifying. The recently released 15th Five-Year Plan for the Pharmaceutical Industry further clarifies policies on pricing, payment, and usage, calling for the full implementation of a whole-cycle drug pricing mechanism and vigorous development of commercial health insurance. One year on, what has this transformation, driven by a quality-upgrade agenda, actually delivered? Can health insurance step out of its scale anxiety and find a true value growth engine?
Accelerated product innovation meets tighter red lines
When many people think of health insurance, their first reaction is "getting compensated when sick." But the category is far broader than that, encompassing critical illness insurance and medical insurance, with popular products like million-yuan medical insurance and inclusive insurance plans (Hui Min Bao) also falling under this umbrella. In September 2025, the financial regulator issued guidance outlining development priorities for four major insurance categories, including commercial medical insurance. Over the past year, structural shifts in the market have become clearly visible on the product side. Million-yuan medical insurance and mid-tier medical insurance have gained wide recognition for their high-leverage advantages, while development of insurance for people with pre-existing conditions has entered a new phase. More specifically, these products are now shifting toward customized development based on disease type, progression, and condition management status. Additionally, new million-yuan medical insurance products that integrate insurance, intelligent agents, and AI-driven health management services have emerged, representing a valuable exploration of technology-empowered health protection.
Numbers reveal the depth of change. A co-founder and general manager of a mutual aid platform noted that in 2025, health insurance premiums reached 997.3 billion yuan, with commercial medical insurance premium income surpassing critical illness insurance for the first time. The industry has shifted from being critical-illness-driven with scale expansion toward a model grounded in medical insurance with value reconstruction. Data shows that in the first half of 2026, health insurance achieved premium income of 643.8 billion yuan, a year-on-year increase of 3.45%. Within the overall insurance premium structure, this segment remains a central topic of discussion.
However, behind the industry's steady development, competition is intensifying. An assistant secretary-general at a university insurance research institute commented that the health insurance market is maintaining stable development overall, but competition has become fiercer, increasing pressure on life insurance companies. Detailed rules for dividend-type critical illness insurance and personal account-based medical insurance, mentioned in last year's document, have yet to be issued, and some market explorations have been corrected. It was suggested that regulators should accelerate the introduction of specific plans for innovative health insurance product development.
The flip side of product innovation is the continuous tightening of regulatory red lines. In the past, some products deviated from the protection-oriented nature of health insurance during design, even being labeled as wealth management tools. Regulators have made it clear they will no longer approve similar high-yield combination products that indirectly breach the pricing rate caps for life insurance. Currently, multiple popular health insurance products marketed for their high cash value plus medical fund accounts have been pulled from the market. How should insurers avoid going off course? One industry expert summarized the answer in three points: making products that truly pay out, making marketing communications clear and honest, and making claims handling robust, with focus areas including underwriting for pre-existing conditions, long-term care and disability coverage, direct payment for specialty drugs, online medication reimbursement, and data integration across hospitals and pharmacies. Another academic voice suggested that from a negative list perspective, insurers should adhere to long-termism in health insurance, build brand IP, and above all avoid actions that harm the industry's overall reputation.
New growth engines emerge as policy continues to encourage payment breakthroughs
Product-side adjustments represent the industry's internal efforts, while intensive policy support at the government level has injected stronger external momentum into this transformation. The 2026 government work report explicitly called for accelerating the development of commercial health insurance for the first time. At the local level, nine municipal departments in Beijing jointly issued 18 measures early this year, including encouraging commercial insurers to appropriately relax underwriting conditions, promoting one-stop settlement between medical insurance and commercial insurance, and guiding commercial insurance to cover treatments outside basic medical insurance, such as rare diseases, to meet the public's diversified health protection needs.
Even greater room for imagination comes from institutional breakthroughs on the payment side. In December 2025, the first edition of the innovative drug catalog for commercial health insurance was officially released, aiming to promote access to innovative drugs through a dual-channel approach combining medical insurance and commercial insurance. A frequently cited set of figures illustrates the growth trajectory of this payment channel: at a working symposium on high-quality health insurance development in January, it was preliminarily estimated that total commercial health insurance payouts for innovative drugs and devices reached approximately 14.7 billion yuan in 2025, sustaining rapid growth for four consecutive years. Meanwhile, commercial health insurance is transitioning from post-hoc claims payer to industrial payer, a role shift that redefines the relationship between health insurance and the pharmaceutical industry.
In light of the pharmaceutical industry plan, experts point to the next growth areas: innovative drug and device payment-type medical insurance, mid-to-high-end medical insurance, long-term care insurance, and disability insurance. The opportunity lies in upgrading from merely covering individuals to building a closed loop of medical care, pharmaceuticals, and insurance, including direct payment for innovative drugs, outcome-based pricing, risk sharing with pharmaceutical companies, and care and rehabilitation ecosystems, moving away from competing on low-priced million-yuan medical insurance volume toward becoming an industrial payer and health management partner. Other growth points and opportunities identified include: first, insurance products paying for innovative drugs and devices; second, drug-insurance linkage leveraging real-world data to optimize risk control and pricing; third, long-term care and disability insurance; and fourth, multi-tier protection products like mid-tier medical insurance that complement basic medical insurance.
Population aging has become one of the core drivers of growing demand for commercial health insurance, while evolving family structures constitute an important social foundation for demand growth. Industry insiders note that although the market shows signs of scale expansion, problems such as low penetration and insufficient conversion of demand into actual coverage remain prominent. From paying claims to managing health, from scale expansion to value reconstruction, the next phase of health insurance development may no longer be merely a leap in premium figures, but a genuine test of protection depth and service warmth.